Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Goodwill & Intangibles (2016 - 2025)

Historic Goodwill & Intangibles for Iradimed (IRMD) over the last 13 years, with Q3 2025 value amounting to $4.8 million.

  • Iradimed's Goodwill & Intangibles rose 1992.69% to $4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.8 million, marking a year-over-year increase of 1992.69%. This contributed to the annual value of $4.3 million for FY2024, which is 2338.61% up from last year.
  • As of Q3 2025, Iradimed's Goodwill & Intangibles stood at $4.8 million, which was up 1992.69% from $4.7 million recorded in Q2 2025.
  • In the past 5 years, Iradimed's Goodwill & Intangibles registered a high of $4.8 million during Q3 2025, and its lowest value of $1.6 million during Q1 2021.
  • Over the past 5 years, Iradimed's median Goodwill & Intangibles value was $3.2 million (recorded in 2023), while the average stood at $3.2 million.
  • Its Goodwill & Intangibles has fluctuated over the past 5 years, first surged by 1127.73% in 2021, then surged by 5678.83% in 2022.
  • Iradimed's Goodwill & Intangibles (Quarter) stood at $1.9 million in 2021, then surged by 56.79% to $2.9 million in 2022, then rose by 19.51% to $3.5 million in 2023, then grew by 23.39% to $4.3 million in 2024, then rose by 12.46% to $4.8 million in 2025.
  • Its last three reported values are $4.8 million in Q3 2025, $4.7 million for Q2 2025, and $4.5 million during Q1 2025.